drugset / Trial / NCT01285245

Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus

NCT01285245

Phase 2 Unknown 16 enrolled Radboud University Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether anakinra is able to reduce insulin resistance. This will be tested in overweighted type I diabetes mellitus patients, which have no residual beta-cell function. By using this patient group, all positive effects on glycemic control should be the consequence of improved insulin sensitivity.

Timeline

Start
2011-04
Primary completion
2011-09
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications